Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
A study on the efficacy of a vaccine against influenza in adults ≥65 years of age
2026-526682-14-00· Phase 3· GlaxoSmithKline Biologicals· Source
Not yet recruiting
Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.
2025-524606-15-00· Phase 3· Tecnimede-Sociedade Tecnico-Medicinal S.A.· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Recruiting
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT07478991· Phase 3· PETHEMA Foundation· Source
Contact: María Solé Rodríguez
Recruiting
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
NCT07695701· Phase 4· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)
2025-524040-35-00· Phase 3· Generate Biomedicines Inc.· Source
Recruiting
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes
2025-521670-34-00· Phase 3· Novartis Pharma AG· Source
Recruiting
LONG NAGOMI™ PMCF STUDY
NCT07399002· Fundación EPIC· Source
Contact: TAMARA GARCIA CAMARERO, MD, PhD
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo
in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
2025-521562-95-00· Phase 3· Mabxience Research S.L.· Source
Recruiting
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
NCT07190690· Fundación EPIC· Source
Contact: Armando Pérez de Prado, MD, PhD
Recruiting
INFLATE Study: Investigation of the Safety and Performance of a Novel PTV Balloon in Patients Undergoing TAVI for Severe Aortic Stenosis
NCT06816485· Biosensors Europe SA· Source
Contact: Antonio Gomez Menchero
Recruiting
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
NCT07252765· Outcomes'10· Source
Contact: Mercedes Blanco Naveira, Medical Adviser. MD
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain
NCT06860945· Hospital Universitario de Valme· Source
Contact: Miguel Raffo, MD
Active, not recruiting
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285· Phase 2· Puma Biotechnology, Inc.· Source
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· Phase 2· Abivax S.A.· Source
Recruiting
DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)
NCT06448637· Fundación EPIC· Source
Contact: IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
Active, not recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· Phase 2· Eli Lilly and Company· Source
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505· Phase 1/2· Gilead Sciences· Source
Active, not recruiting
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)
NCT06273293· Fundación EPIC· Source
Contact: SANTIAGO J CAMACHO FREIRE, MD, PhD
Active, not recruiting
Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions
NCT06272643· Fundación EPIC· Source
Active, not recruiting
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934· Phase 2· Gilead Sciences· Source
Recruiting
Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI
NCT06353594· Hospital Universitario La Fe· Source
Contact: ANTONIO E GÓMEZ MENCHERO, PI
Active, not recruiting
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT06321757· Fundación EPIC· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698· Hamilton Health Sciences Corporation· Source
Contact: Antonio Enrique Gómez Menchero, MD (principal investigator)
Active, not recruiting
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
NCT05952206· Phase 3· iVascular S.L.U.· Source
Recruiting
Coroflex® ISAR NEO PMCF Study
NCT05698732· Fundación EPIC· Source
Contact: koldobika García San Román, MD, PhD
Active, not recruiting
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472· Swedish Orphan Biovitrum· Source
Active, not recruiting
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973· Terumo Europe N.V.· Source
Active, not recruiting
Sequent Extended Study
NCT05788432· Fundación EPIC· Source
Active, not recruiting
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
NCT05599061· Fundación EPIC· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Abivax S.A.· Source
Active, not recruiting
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source
Active, not recruiting
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· Phase 3· AriBio Co., Ltd.· Source
Showing 50 of 58.